Effects of Anti-IL-13 on nasal allergen challenge
Published Online: June 30, 2011
A range of specific biologic therapies directed against the Th2 cytokines IL-4, IL-5 and IL-13 have recently been assessed in clinical studies in patients with allergy and asthma.
In an upcoming issue of The Journal of Allergy and Clinical Immunology (JACI), Nicholson et al evaluated the effects of an anti-IL-13 blocking antibody compared with placebo on repeated nasal allergen challenge (NAC) responses in hay fever patients out of season. Serial non-invasive sampling of nasal mucosal lining fluid (MLF) was performed with synthetic absorptive matrix (SAM) strips, prior to measurement of a range of cytokines and chemokines.
Anti-IL-13 had specific pharmacodynamic action in this NAC model, causing profound inhibition of nasal MLF IL-13 responses. There was found to be a considerable variation between individuals in terms of the late phase IL-5 and IL-13 response, and anti-IL-13 had a possible effect on nasal symptoms in a subgroup with high late phase nasal IL-13 at screening.
Nasal challenge models with serial non-invasive sampling have considerable potential to study the molecular basis of mucosal inflammatory responses. The authors conclude that nasal challenge models can also be used to predict responders and monitor effects of specific therapy for allergy and asthma.
The Journal of Allergy and Clinical Immunology (JACI) is the official scientific journal of the AAAAI, and is the most-cited journal in the field of allergy and clinical immunology.